



**Validation**Institute

# 2024 Validation Report

**Review for: US-Rx Care**  
**Validation Achieved: Outcomes**  
**Valid through: September 2024**



# Company Profile

---



**Category:** Pharmacy Benefit Management

**Website:** <https://usrxcare.com/>

**Public or Private:** Private

**Year Established:** 2007

**CEO:** Renzo Luzzatti

**Company contact:** rluzzatti@us-rxcare.com

**Description:**

**US-RX Care** delivers Pharmacy Benefit Risk Management unlike any other service offered by pharmacy benefit managers (PBMs) of any kind, anywhere in the US.

**US-RX Care** provides fiduciary pharmacy risk management to self-insured employers with a singular focus on balancing cost and quality care in the best interest of plan sponsors and their plan participants.

**US-RX Care** is obsessed with service and quality of care - with no financial conflict of interest, no hidden profits and unrestricted transparency.





# Claim Assertion for Validation

---

US Rx Care significantly improves patients' diabetes, hypertension antagonist, and statin medication adherence.





# Method / Calculation / Examples

---

Applying Medicare Stars specifications, the following three measures were performed:

- Medication adherence for diabetes
- Medication adherence for hypertension (renin angiotensin antagonists RAS); and
- Medication adherence for hypertension (statins)

For each measure, people are considered adherent if they fill their prescription often enough to cover 80% or more of the days they are supposed to be taking the medication using proportion of days covered to measure adherence (the CMS standard).

The case study group had 46,531 members on average for the time period. The measures were tracked annually from 2016. US-Rx Care implemented its adherence programs starting January 2017.


The national threshold for awarding five stars was tracked for the same time periods.





# Findings & Validation

Graphs 1, 2, and 3 show the medication adherence performance for diabetes, hypertension, and statin drugs from 2016 through 2022. The difference between the 2016 and 2022 performance was statistically significant for all three measures. In addition, the adherence performance was high enough to merit 5 stars on CMS’s Star Rating method five of the six years in diabetes and hypertension RAS drugs; and six of the six years for statin drugs.




Graph 1: Medication Adherence Diabetes 2016 – 2022





# Findings & Validation




Graph 2: Medication Adherence Hypertension (RAS) 2016 – 2022





# Findings & Validation

---



Graph 3: Medication Adherence Statins 2016 – 2022





# Limitations

---

This analysis is based upon federal agency CMS's measure specifications and Star standards as of the time of publication. These definitions could change, which might change the intervention's performance.







# Validation and Credibility Guarantee

---

**US-Rx Care's diabetes, hypertension, and statin medication adherence as measured by CMS Medicare Stars achieved validation for Outcomes.**

Validation Institute is willing to provide up to a \$25,000 guarantee as part of their Credibility Guarantee Program. To learn more, visit

<https://validationinstitute.com/credibility-guarantee/>.

## Savings

Can reduce health care spending per case/participant or for the plan/purchaser overall.

## Outcomes

Product/solution has measurably improved an outcome (risk, hba1c, events, employee retention, etc.) of importance.

## Metrics

Credible sources and valid assumptions create a reasonable estimate of a program's impact.

## Contractual Integrity

Vendor is willing to put a part of their fees "at risk" as a guarantee.





**Validation Expiration: September 2024**

# CERTIFICATE OF VALIDATION

---

<b>Applicant:</b>	<b>US-Rx Care</b> 4600 Sheridan Street, Ste. 200, Hollywood, Florida 33021, USA
<b>Product:</b>	Medicare Medication adherence for diabetes, hypertension, and statin drugs
<b>Claim:</b>	US Rx Care significantly improves a plan's diabetes, hypertension antagonist, and statin medication adherence
<b>Validation Achieved:</b>	<b>Validated for Outcomes</b>
<b>Validation Award Date:</b>	March 2023

---

**Linda K. Riddell, MS**  
**Chief Data Scientist**  
**Validation Institute**

---

**Vidar Jorgensen**  
**Chief Executive Officer**  
**Validation Institute**





# About Validation Institute

---

**Validation Institute** is a professional community that advocates for organizations and approaches that deliver better health value - stronger health outcomes at lower cost. We connect, train, and certify health care purchasers, and we validate and connect providers delivering superior results. Founded in 2014, the mission of the organization has consistently been to help provide transparency to buyers of health care.

## Validation Review Process

Validation Institute has a team of epidemiologists and statisticians who review each program. The team focuses on three components:

- Evidence from published literature that a similar intervention had similar results.
- The reliability and credibility of the data sources.
- The rigor of the approach to calculating results.

To achieve validation, the program has to satisfy each of these components. VI's team then summarizes the review into a report which is publicly available. Details of VI's review are available with the program's permission.

